Axios on MSN

CSL Seqirus' Wake County factory makes flu vaccines for the whole world

Nestled into the pines of southern Wake County is the largest cell-based flu vaccine maker in the world. Why it matters: CSL ...
irblog.prnewswire.com

Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response

SUMMIT, N.J., Aug. 30, 2019 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore from ...
Fierce Pharma

CSL Seqirus blasted for ‘multiple and prolonged deficiencies’

A U.K. drug marketing watchdog has slammed CSL Seqirus for “multiple and prolonged deficiencies” in its systems, governance ...
irblog.prnewswire.com

Seqirus Announces Further Advances in Cell-Based Influenza Vaccine Technology

SUMMIT, N.J., April 15, 2019 /PRNewswire/ -- Seqirus, a leading innovator in influenza protection, today announced it will file an Annual Strain Update with the U.S. Food and Drug Administration (FDA) ...
FiercePharma

Flu vaccine maker Seqirus completes $156M expansion at North Carolina fill-finish facility

First started in 2018, Seqirus completed a $156 million expansion of its Holly Springs, North Carolina, facility that produces influenza vaccines. (Seqirus) (Seqirus) Seqirus completed a $156 million ...

CSL vaccines unit slammed over UK compliance failures

Britain’s drugs marketing watchdog said CSL Seqirus “has brought discredit upon and reduced confidence in the pharmaceutical ...
FT Markets

CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign

HOLLY SPRINGS, N.C. , Sept. 29, 2026 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL ), today announced expanded availability of influenza vaccine in the United States following the ...
Business Wire

Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market

Seqirus is now shipping its portfolio of over 50 million doses of influenza vaccines to the U.S. market in preparation for the upcoming 2017-2018 influenza season. Seqirus utilizes both egg and ...
Business Wire

Seqirus Announces Next Major Advancement in Cell-Based Influenza Vaccine Technology

HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today announced the next major advancement in the use of cell-based technology at ...
Medindia

Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

SUMMIT, N.J., March 5, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX ® QUADRIVALENT ...
Forbes

For Seqirus, mRNA Offers The Next Big Breakthrough In Flu Vaccines

Doses of vaccine in the packaging system. Spare a bit of sympathy for our flu vaccine makers. Chris Larkins, SVP of Global Operations at Seqirus. “For flu, chasing variants is such a challenge in ...
Nasdaq

Seqirus Bags $35 Mln U.S. Govt. Contract To Develop Two Pandemic Influenza Vaccines

(RTTNews) - Seqirus, an influenza prevention provider and an arm of CSL Limited (CSL.AX), on Monday said the Biomedical Advanced Research and Development Authority or BARDA, has chosen the company to ...